Cell therapy is the introduction of new cells into a patient’s body to grow, replace, or repair damaged tissue in order to treat a disease. A variety of different types of cells can be used in cell therapy, including stem cells, lymphocytes, and dendritic cells. Cell therapies can use cells from the patient’s own body (autologous) or from a donor (allogenic). Many cell therapies use adult cells that have been genetically reprogrammed and capable of becoming one of many types of cells inside a patient’s body. This technology may enable the development of unlimited types of specific human cells needed for therapeutic purposes.
Gene therapy seeks to modify or introduce genes into a patient’s body with the goal of treating, preventing, or potentially curing a disease. Examples of gene therapy approaches include replacing a mutated gene that causes disease with a functional copy or introducing a new, correct copy of a gene into the body.
Market Dynamics
Cell and gene therapy plays a major role in modern healthcare, as it provides concepts and techniques that can be used in gene regulation, cell-cell interactions, regenerative capacity, and remodeling. Thus, key market players are focused on adopting various growth strategies such as product/platform launches and others, which in turn is expected to fuel the market growth over the forecast period. For instance, on April 4, 2023, AmerisourceBergen, a global healthcare company, announced the launch of its Cell and Gene Therapy (CGT) Integration Hub, a system that can be integrated with biopharma or provider-facing platforms to facilitate real-time data exchange and help orchestrate services across the treatment development and patient journey.
Furthermore, The CGT Integration Hub, which is platform-agnostic and powered by AmerisourceBergen’s innovative customer relationship management (CRM) system, aims to streamline the path-to-care process, in part, by providing physicians and patient services teams with enhanced visibility across the therapy development and delivery process. Through platform integrations, the CGT Integration Hub can:
- Speed up the benefits investigation process so that after physicians enter patient enrollment data, they can get a decision on the patient's coverage almost immediately.
- To facilitate patient scheduling, give doctors and care managers real-time access to information on the status of the development of the therapy and transportation.
- Inform case managers of any status changes, such as postponed arrival dates, so they can contact patients and caregivers in advance to amend any scheduled treatment-related activities or stays, as necessary.
Key features of the study:
- This report provides an in-depth analysis of the global cell and gene therapy market and provides market size (US$ Billion) and compound annual growth rate (CAGR) for the forecast period (2023–2030), considering 2022 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global cell and gene therapy market based on the following parameters–Company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Novartis International AG, Pfizer, Inc., Sanofi S.A., Amgen, Inc., Regeneron Pharmaceuticals, Inc., Bluebird Bio, Inc. (Celgene Corporation) , Biogen Inc., uniQure N.V., JCR Pharmaceuticals Co. Ltd., Gene Biotherapeutics, Kolon TissueGene, Inc., Horama S.A., MeiraGTx Limited, Gilead Sciences, Inc., Organogenesis, Inc., Orchard Therapeutics Plc., Freeline Therapeutics Ltd. , Bristol-Myers Squibb Company, PTC Therapeutics, Inc., Spark Therapeutics, Inc. and Biomarin Pharmaceutical Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global cell and gene therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cell and gene therapy market
Detailed Segmentation:
- Global Cell and Gene Therapy Market, By Therapy Type:
- Cell Therapy
- Stem Cells
- T Cells
- Dendritic Cells
- NK Cells
- Gene Therapy
- Germline Gene Therapy
- Somatic Gene Therapy
- Global Cell and Gene Therapy Market, By Application:
- Dermatology
- Musculoskeletal
- Oncology
- Immunology
- Cardiology & Neurology
- Others (Urinary Problems, Infectious Disease, Ophthalmic, Diseases, Retinal Diseases, And Others)
- Global Cell and Gene Therapy Market, By End user:
- Hospitals
- Clinics
- Others (Research Institutes, Academic Institutes, etc.)
- Global Cell and Gene Therapy Market, By Region:
- North America
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Novartis International AG
- Pfizer, Inc.
- Sanofi S.A.
- Amgen, Inc.
- Regeneron Pharmaceuticals, Inc.
- Bluebird Bio, Inc. (Celgene Corporation)
- Biogen Inc.
- uniQure N.V.
- JCR Pharmaceuticals Co. Ltd.
- Gene Biotherapeutics
- Kolon TissueGene, Inc.
- Horama S.A.
- MeiraGTx Limited
- Gilead Sciences, Inc.
- Organogenesis, Inc.
- Orchard Therapeutics Plc.
- Freeline Therapeutics Ltd.
- Bristol-Myers Squibb Company
- PTC Therapeutics, Inc.
- Spark Therapeutics, Inc.
- Biomarin Pharmaceutical Inc.
